Digital therapeutics company PneumoWave (formerly known as Altair Medical) announced today the commencement of a second clinical trial in partnership with the Research & innovation Department at NHS Greater Glasgow & Clyde (NHS GG&C).
The TARS trial (Toxicology Advance Respiratory System), led by Prof. David Lowe (Consultant in Emergency Medicine at the Queen Elizabeth University Hospital, Glasgow, and Clinical Director of the Scottish Health Innovation Partnership), will study patients at risk of death from respiratory depression presenting to the Emergency Department following ingestion of an illicit substance.
TARS builds on work undertaken in PneumoWave and NHS GG&C’s first clinical collaboration, the Chief Scientist Office funded CARP trial led by Dr Chris Carlin, which will continue in parallel to collect data from a range of respiratory conditions
Both trials form part of PneumoWave’s extensive program of clinical research in leading academic institutions across the UK, covering a range of conditions, as they build remote monitoring and digital therapeutic solutions to reduce high-impact adverse events affecting the respiratory system.
Dr Bruce Henderson, founder and CEO of PneumoWave, commented “The TARS study will allow PneumoWave to further develop and validate our technology in patients at risk of life-threatening side effects from medication and assist in developing our remote monitoring and digital therapeutic solutions that aim to prevent these deaths. We are excited to utilise the expertise within the NHS GG&C R&D team to achieve this goal”.
Prof. David Lowe added “The ability to continuously monitor the breathing of patients and detect problems in real time, both in hospital and at home, is an enormous unmet need. This is crucial work as we strive to reduce the impact of unnecessary deaths which is a priority in Scotland and worldwide. The study demonstrates the NHS working in partnership with industry and academia to develop innovative solutions with the potential to transform care.’